ABL1 and systemic sclerosis: Finally, the third-generation kinase inhibitor bosutinib, able to simultaneously inhibit c-Abl and Src, was reported to reduce type I collagen, fibronectin and α-SMA production in SSc dermal fibroblasts in vitro [132] and to exert antifibrotic effects in vivo, with a significant decrease in myofibroblast activation and profibrotic gene expression in TBRIcaCol1a2Cre-transgenic mice [133].